7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 
      
    		                                               
      operating activities
    		                                               
      net income
    		-7,742,000 2,523,000 -24,526,000 -12,532,000 -19,717,000 -19,796,000 -17,875,000 -19,312,000 -20,104,000 -17,094,000 -16,339,000 -21,932,000 -17,567,000 -14,192,000 -15,765,000 -21,321,000 -19,158,000 -19,387,000 -16,381,000 -17,042,000 -18,755,000 -14,087,000 -13,861,000                         
      non-cash items:
    		                                               
      depreciation
    		11,000 11,000 330,000 333,000 336,000 356,000 355,000 359,000 369,000 342,000 334,000 307,000 343,000 383,000 394,000 427,000 447,000 436,000 443,000 487,000 490,000 501,000 500,000 1,521,000                        
      loss on impairment of leasehold improvements and lab equipment
    		0 0 2,811,000                                             
      stock-based compensation expense
    		1,263,000 864,000 3,564,000 1,632,000 2,160,000 3,180,000 2,014,000 1,723,000 2,483,000 2,964,000 2,131,000 1,667,000 1,715,000 2,064,000 1,736,000 1,431,000 1,615,000 1,743,000 1,635,000 1,431,000 1,688,000 1,597,000 1,445,000 5,283,000 -2,268,000 2,262,000 1,522,000                     
      change in fair value of contingent consideration
    		268,000 260,000 299,000 1,890,000 344,000 211,000 180,000 227,000 205,000 -636,000 273,000 1,609,000 215,000 208,000 201,000 193,000 856,000 694,000 129,000 125,000 120,000 116,000 112,000 203,000 -506,000 5,000 125,000 -1,690,000 -5,801,000 1,041,000 -848,000 1,162,000 307,000 -1,169,000 1,059,000 1,308,000 8,000 8,000 244,000         
      non-cash royalty revenue
    		-249,000 -526,000 -448,000 -515,000 -572,000 -571,000 -593,000 -1,200,000 -723,000 -766,000 -1,178,000 -2,260,000 -2,345,000 -1,685,000 -1,363,000 -2,145,000 -1,860,000 -1,144,000 -959,000 -1,354,000 -696,000 -689,000 -656,000 -677,000                        
      non-cash interest expense
    		23,000 27,000 28,000 29,000 28,000 34,000 36,000 43,000 46,000 169,000 197,000 309,000 428,000 479,000 506,000 558,000 761,000 760,000 771,000 791,000 1,074,000 1,053,000 1,039,000 993,000                        
      net accretion and amortization of investments in marketable securities
    		-541,000 -668,000 -718,000 -923,000 -983,000 -676,000 -553,000 -619,000 -658,000 -534,000 -385,000 -224,000 -81,000 83,000 168,000 246,000 300,000 294,000 159,000 139,000 31,000 42,000 -2,000                         
      net change in operating items:
    		                                               
      accounts receivable
    		120,000 157,000 1,227,000 -801,000 159,000 372,000 -363,000 395,000 443,000 50,000 -1,312,000 483,000 135,000 -657,000 -414,000 768,000 -369,000 -33,000 47,000 -237,000 33,000 -36,000 132,000 1,184,000 -349,000 -1,116,000 508,000 -1,813,000 1,387,000 -286,000 -317,000 -325,000 -6,495,000 14,296,000 -7,605,000 674,000 177,000 -784,000 668,000 -3,419,000 5,785,000 1,148,000 -2,886,000 -35,000 -3,083,000 2,640,000 -1,409,000 
      prepaid expenses and other assets
    		1,040,000 -1,053,000 413,000 1,153,000 1,185,000 116,000 -156,000 1,097,000 -1,463,000 -109,000 -468,000 2,403,000 1,153,000 381,000 -1,507,000 -958,000 374,000 416,000 -857,000 -1,102,000 317,000 472,000 -439,000 526,000   2,110,000 -757,000 -113,000 -465,000 687,000 -916,000 92,000 255,000 -264,000 -699,000 1,157,000 -300,000 -273,000 -310,000 988,000 -740,000 221,000 -390,000 -626,000 -239,000 482,000 
      accounts payable and accrued liabilities
    		145,000 -7,601,000 4,545,000 20,000 -3,564,000 2,861,000 -2,024,000 465,000 1,001,000 -848,000 -6,376,000 3,760,000 -204,000 3,762,000 -2,102,000 1,326,000 1,167,000 2,214,000 -2,796,000 1,813,000 1,251,000 2,204,000 -3,602,000 -2,948,000 -350,000 3,634,000 -2,746,000 -2,360,000 173,000 5,108,000 -4,187,000 2,541,000 -4,010,000 6,114,000 -3,909,000 913,000 -929,000 1,158,000 -1,116,000 -4,897,000 9,759,000 -9,359,000 2,008,000 3,896,000 3,300,000 -1,994,000 1,051,000 
      change in deferred license revenue
    		0 -9,622,000 -812,000 -477,000 -123,000 -513,000 -244,000  -3,221,000                                       
      other liabilities
    		-155,000 -121,000 -104,000 -124,000 -156,000 -78,000 -72,000 -155,000 -142,000 -73,000 -74,000 -124,000 -132,000 -74,000 -75,000  -125,000 -2,000 -116,000  -134,000 -20,000 -131,000 -219,000   -87,000                     
      net cash from operating activities
    		-5,817,000 -15,749,000 -13,391,000 -10,315,000 -20,736,000 -14,504,000 -19,295,000 -17,292,000 -21,784,000 -19,559,000 -27,301,000 -16,990,000 -18,692,000 -20,293,000 20,619,000 -19,606,000 -16,036,000 -14,009,000 -17,881,000 -15,013,000 -12,174,000 -8,801,000 -15,453,000 -47,536,000 -5,865,000 -1,025,000 -16,580,000 -54,662,000 4,418,000 2,345,000 -19,967,000 -32,960,000 -10,602,000 12,457,000 -17,535,000 -43,173,000 2,092,000 -5,258,000 -11,546,000   1,172,000 -17,843,000 -5,701,000 1,290,000 -17,165,000 9,155,000 
      capex
    		0 0 0 -86,000 0 -1,000 -95,000 0 -32,000 -859,000 -117,000 -134,000 -91,000 -212,000 -75,000 -58,000 -20,000 -632,000 -99,000 -152,000 -11,000 0 0 -334,000 -15,000 -209,000 -31,000 -901,000 188,000 -177,000 -248,000 -6,726,000 2,583,000 302,000 -3,423,000 -3,828,000 786,000 -678,000 -276,000   -242,000 -141,000 -904,000 94,000 89,000 -335,000 
      free cash flows
    		-5,817,000 -15,749,000 -13,391,000 -10,401,000 -20,736,000 -14,505,000 -19,390,000 -17,292,000 -21,816,000 -20,418,000 -27,418,000 -17,124,000 -18,783,000 -20,505,000 20,544,000 -19,664,000 -16,056,000 -14,641,000 -17,980,000 -15,165,000 -12,185,000 -8,801,000 -15,453,000 -47,870,000 -5,880,000 -1,234,000 -16,611,000 -55,563,000 4,606,000 2,168,000 -20,215,000 -39,686,000 -8,019,000 12,759,000 -20,958,000 -47,001,000 2,878,000 -5,936,000 -11,822,000   930,000 -17,984,000 -6,605,000 1,384,000 -17,076,000 8,820,000 
      investing activities
    		                                               
      purchase of investments in marketable securities
    		-51,300,000 -28,498,000 -34,716,000 -43,191,000 -40,336,000 -32,585,000 -25,397,000 -24,019,000 -7,085,000 -29,200,000 -20,205,000                                     
      proceeds from sale of property and equipment
    		0       0     0             -7,000 9,000 0 23,000                   
      disposition of investments in marketable securities
    		41,281,000 44,100,000 46,065,000 56,688,000 28,350,000 42,415,000 37,186,000 46,244,000 17,526,000 31,500,000 37,000,000                                     
      acquisition of property and equipment
    		   -86,000 0 -1,000 -95,000 0 -32,000 -859,000 -117,000 -134,000 -91,000 -212,000 -75,000 -58,000 -20,000 -632,000 -99,000 -152,000 -11,000   -334,000 -15,000 -209,000 -31,000 -901,000 188,000 -177,000 -248,000 -6,726,000 2,583,000 302,000 -3,423,000 -3,828,000 786,000 -678,000 -276,000   -242,000 -141,000 -904,000 94,000 89,000 -335,000 
      net cash from investing activities
    		-10,019,000 15,611,000 11,349,000 13,411,000 -11,986,000 9,829,000 11,694,000  10,429,000 1,441,000 16,678,000 12,682,000 -13,738,000 -13,830,000 -60,056,000 -8,121,000    -49,976,000 14,097,000                       -42,515,000 42,795,000 -42,903,000 -335,000 
      financing activities
    		                                               
      issuance of common shares pursuant to the open market sale agreement
    		   -1,000 0 22,359,000 21,765,000 3,852,000 1,396,000 4,742,000 19,862,000  8,973,000 0 268,000  44,736,000 4,274,000 26,419,000  48,760,000 5,045,000 12,315,000   229,000 2,248,000                     
      issuance of common shares pursuant to exercise of stock options
    		794,000 453,000 2,653,000 1,422,000 1,590,000 2,011,000 2,454,000 1,000 0 0 259,000                                     
      issuance of common shares pursuant to espp
    		50,000 0 131,000          159,000 0 236,000  214,000 0 247,000                             
      net cash from financing activities
    		844,000 453,000 2,784,000 1,421,000 1,775,000 24,370,000 24,430,000 3,807,000 1,681,000 4,742,000 20,417,000 11,084,000 9,132,000 113,000 11,485,000 59,121,000 46,952,000 4,289,000 26,874,000 20,210,000 49,096,000 4,959,000 12,481,000 18,908,000 16,070,000 -57,000 2,536,000 55,211,000 -300,000 -53,632,000 54,367,000 49,261,000 57,000 -350,000 354,000 12,562,000 -370,000 331,000 115,000 143,754,000 -844,000 -141,860,000 142,820,000 59,992,000 450,000 -59,055,000 59,289,000 
      effect of foreign exchange rate changes on cash and cash equivalents
    		-12,000 21,000 4,000 -33,000 5,000 -8,000 -13,000 14,000 8,000 -1,000 4,000 -4,000      0 -44,000 112,000 0 -46,000 -10,000 92,000 -81,000 19,000 38,000  492,000 204,000 -565,000  502,000 401,000 424,000  -773,000 -3,057,000 3,006,000   3,401,000 -2,434,000 -1,216,000    
      (decrease) / increase in cash and cash equivalents
    		                                               
      cash and cash equivalents, beginning of period
    		0 0 36,330,000 0 0 0 26,285,000 0 0 0 30,776,000 0 0 0 109,282,000 0 0 0 52,251,000 0 0 0 31,799,000 -41,930,000      -41,831,000 54,292,000 -799,000 -5,639,000 6,438,000 23,413,000 123,809,000 -101,802,000 -22,007,000 166,779,000 -135,018,000 -25,071,000 160,089,000 72,187,000 -16,550,000 -49,090,000 65,640,000 68,717,000 
      cash and cash equivalents, end of period
    		-15,004,000 336,000 37,076,000 4,484,000 -30,942,000 19,687,000 43,101,000 8,754,000 -9,666,000 -13,377,000 40,574,000 6,772,000 -23,316,000 -34,010,000 81,330,000 31,399,000 46,929,000 -48,467,000 79,421,000 -44,667,000 51,019,000 19,483,000 26,416,000 -58,283,000      -2,268,000 12,461,000 39,067,000 -8,987,000 -5,639,000 29,851,000 -3,217,000 -16,340,000 -101,802,000 144,772,000 -14,310,000 -26,116,000 -25,071,000 232,276,000 -5,990,000 -7,090,000 -49,090,000 134,357,000 
      increase in cash and cash equivalents
    		 336,000 746,000    16,816,000    9,798,000    -27,952,000 31,399,000 46,929,000 -48,467,000 27,170,000 -44,667,000 51,019,000         39,563,000 -41,831,000 39,866,000 -3,348,000 -12,077,000 6,438,000 -127,026,000 85,462,000 -79,795,000 -22,007,000   -185,160,000 160,089,000 10,560,000 42,000,000 -114,730,000 65,640,000 
      loss on impairment of lab equipment
    		   0                                            
      gain on sale of property and equipment
    		       0     0             7,000 -9,000 0                    
      issuance of common shares pursuant to exercise of espp
    		     0 211,000 -46,000 285,000 0 296,000                                     
      increase / (decrease) in cash and cash equivalents
    		                      -5,383,000                         
      increase/(decrease) in cash and cash equivalents
    		    -30,942,000                                           
      deferred license revenue
    		          -4,104,000 -3,008,000 -2,352,000 -11,025,000 38,840,000                                 
      net cash provided by/(used in) investing activities
    		                                               
      issuance of common shares pursuant to share purchase agreement
    		           0 0 0 10,973,000                                 
      decrease in cash and cash equivalents
    		       8,754,000 -9,666,000                                       
      issuance of common shares pursuant to the atm
    		                                               
      supplemental cash flow information
    		                                               
      preferred shares dividends accrued
    		               -574,000 -5,087,000 -3,266,000 -3,212,000 -3,123,000 -3,027,000 -2,995,000 -2,978,000 -8,357,000 -5,554,000 47,000 2,715,000 7,524,000 26,000                   
      purchase of investments
    		            -32,647,000 -22,638,000 -61,981,000  -11,000 -52,115,000 -2,030,000  -2,992,000 -1,543,000 -24,369,000                         
      disposition of investments
    		            19,000,000 9,000,000 2,000,000  16,000,000 14,000,000 20,350,000  19,600,000 24,980,000 21,968,000                         
      issuance of common shares pursuant to exercise of options
    		            0 113,000 8,000 -115,000 2,002,000 15,000 208,000 33,000 336,000 -86,000 166,000   -286,000 288,000 947,000 -300,000 632,000 103,000 39,000 57,000 3,000 1,000 116,000 75,000 -114,000 115,000 1,535,000 -823,000 319,000 620,000 2,348,000 120,000 -1,776,000 1,924,000 
      (decrease)/increase in cash and cash equivalents
    		                                               
      unrealized foreign exchange losses
    		                 0 44,000  0 46,000 10,000                         
      unrealized foreign exchange gains
    		                                               
      net equity investment loss
    		                   1,000                            
      lease liabilities
    		                                               
      investment in genevant
    		                   0                            
      issuance of common shares pursuant to exercise of espp options
    		                                               
      issuance of common shares pursuant to the open market sales agreement
    		                                               
      restructuring accrual
    		                                               
      net cash (used) provided by investing activities
    		                                               
      net cash provided (used) by investing activities
    		                  18,221,000                             
      deferred income tax benefit
    		                       0    0                    
      loss on sale of property and equipment
    		                                               
      impairment of intangible assets
    		                       0    0            1,017,000        
      impairment of goodwill
    		                       0                        
      proceeds from sale of future royalties
    		                                               
      items not involving cash:
    		                                               
      net equity investment gain
    		                                               
      net cash from / (used in) investing activities
    		                      -2,401,000                         
      net income for the period
    		                          -23,251,000   20,520,000 -17,429,000 -72,813,000 6,655,000 372,000 -18,627,000 -364,569,000 110,405,000 -114,126,000 -15,874,000   -2,897,000 -11,989,000     
      unrealized foreign exchange (gains) losses
    		                         -19,000 -38,000  -492,000 -204,000 565,000  -504,000 -399,000 -425,000  775,000 3,057,000 -3,006,000   9,696,000 -7,057,000 -973,000 -4,636,000 1,450,000 -59,000 
      site consolidation non-cash portion
    		                                               
      net change in non-cash operating items:
    		                                               
      accrued revenue
    		                                         2,430,000 -1,126,000 -399,000 -181,000 428,000 -208,000 
      investment tax credits receivable
    		                          98,000    -2,000   309,000 -15,000             
      deferred revenue
    		                           -2,417,000 421,000 276,000 -1,022,000 9,466,000 -6,086,000 -8,045,000 7,392,000 -370,000 -483,000 -56,000 -157,000 -16,101,000 2,677,000 1,625,000 -1,291,000 13,977,000 -1,261,000 -11,834,000 12,289,000 
      site consolidation accrual
    		                         -501,000 -139,000 1,651,000 -381,000 -968,000 1,029,000                 
      acquisition of investments
    		                                           -41,691,000 42,701,000   
      proceeds from the sale of future royalties
    		                                               
      promissory note repayment
    		                              -12,001,000                 
      proceeds from sale of preferred shares, net of issuance costs
    		                                               
      issuance of common shares pursuant to open market sales agreement
    		                                               
      initial investment in genevant
    		                                               
      interest paid
    		                                               
      gain on investment
    		                                               
      equity investment loss
    		                        178,000 -1,317,000 4,651,000 2,489,000                    
      acquisition of short and long-term investments
    		                                               
      disposition of short and long-term investments
    		                                               
      net cash from (used) in investing activities
    		                        6,183,000 -51,061,000 61,033,000  9,398,000 90,646,000 -75,666,000  6,695,000 -24,585,000 23,195,000  84,513,000 -71,811,000 -13,582,000   -47,873,000 37,546,000     
      proceeds from sale of series a preferred shares, net of issuance costs
    		                              66,265,000                 
      non-cash transactions:
    		                                               
      net (loss)/income for the period
    		                                               
      depreciation of property and equipment
    		                         -4,000 509,000 1,684,000 -81,000 -24,000 602,000 1,434,000 113,000 146,000 334,000 801,000 39,000 35,000 217,000 436,000 6,000 27,000 120,000 396,000 -16,000 15,000 134,000 
      gain on equity investment
    		                                               
      prepaid expenses and other current assets
    		                                               
      other non-current liabilities
    		                                               
      acquisition of short-term investments
    		                                               
      disposition of short-term investments
    		                         -50,845,000 61,055,000                37,363,000     
      increase in cash, cash equivalents, and restricted investment
    		                         -52,124,000 47,027,000                     
      cash, cash equivalents, and restricted investment, beginning of period
    		                         47,027,000 36,942,000                     
      cash, cash equivalents, and restricted investment, end of period
    		                         -5,097,000 83,969,000                     
      other assets
    		                          167,000                     
      stock-based compensation
    		                                               
      change in fair value of warrant liability
    		                                  22,000 -520,000 158,000 -7,000 -161,000   -3,247,000 1,223,000 5,243,000 10,953,000 -19,429,000 13,616,000 
      deferred rent and inducements
    		                                               
      disposition (acquisition) of investments
    		                                               
      issuance of common shares pursuant to exercise of warrants
    		                                  353,000       -6,000 25,000 1,167,000 330,000 -802,000 888,000 
      effect of foreign currency rate changes on cash and cash equivalents
    		                                               
      investment tax credits received
    		                                               
      net (loss) for the period
    		                                               
      stock-based compensation - research, development, collaborations and contract expenses
    		                            -566,000 1,084,000 783,000 6,768,000 -587,000 433,000 2,622,000 8,396,000 240,000 -428,000 2,947,000 5,198,000 1,294,000 -780,000 2,157,000 2,017,000 -466,000 -56,000 848,000 
      stock-based compensation - general and administrative expenses
    		                            -267,000 622,000 172,000 4,370,000 -537,000 167,000 1,881,000 26,309,000 -17,897,000 14,627,000 4,965,000 9,392,000 786,000 3,269,000 777,000 821,000 -170,000 -51,000 340,000 
      deferred lease incentives
    		                                               
      disposition (acquisition) of short and long-term investments
    		                            9,187,000 90,821,000 -75,418,000  4,112,000 -24,887,000 26,618,000  83,727,000 -71,133,000 -13,306,000         
      investment tax credit received
    		                                0               
      acquired property and equipment in trade payables
    		                                 -1,355,000 1,427,000             
      deferred income taxes
    		                                               
      acquisition of restricted investment
    		                                               
      cash acquired through acquisition
    		                                               
      proceeds from loan payable
    		                                               
      proceeds from issuance of common shares, net of issuance costs
    		                                         -142,173,000 142,175,000    56,477,000 
      acquisition of property and equipment not yet paid
    		                                               
      acquisition of arbutus inc. net of cash acquired
    		                                               
      deferred expenses
    		                                           111,000 -1,000 2,000 55,000 
      fair value of warrants exercised on a cashless basis
    		                                               
      acquisition of arbutus inc. excluding cash acquired
    		                                               
      cash acquired through acquisition of oncore
    		                                          324,000     
      acquisition of oncore exclusing cash acquired
    		                                          381,618,000     
      warrant issuance costs
    		                                               
      fair value of warrants issued in conjunction with public offering
    		                                               
      loss for the period
    		                                            -2,523,000 11,903,000 -17,984,000 
      effect of foreign exchange rate changes on cash & cash equivalents
    		                                             4,393,000 -2,469,000 
      income for the year
    		                                               
      fair value of warrants issued in conjunction with debt facility
    		                                               
      inventory
    		                                               
      net cash (used in) operating activities
    		                                               
      proceeds from issuance of common shares and warrants, net of issuance costs
    		                                               
      cash and cash equivalents, beginning of year
    		                                               
      cash and cash equivalents, end of year
    		                                               
      foreign exchange (gains) losses arising on foreign currency cash balances
    		                                               
      foreign exchange gains arising on foreign currency cash balances
    		                                               
      proceeds from (acquisition of) short-term investments, ne
    		                                               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.